secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001601830-23-000048
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports stockholder meeting results; all four proposals approved
--------------------------------------------------------------------------

- Terry-Ann Burrell and Christopher Gibson elected Class II directors with 163.4M and 169.4M votes for.
- Advisory vote on executive compensation approved with 178.8M for (98.9% of votes cast).
- Stockholders favored an annual advisory vote on executive compensation (180.1M for 1 year).
- Ratification of Ernst & Young as independent auditor for FY 2023 approved with 210.6M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/rxrx-20230616.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer